Yipinhong's Portfolio Company Fendi Pharma Receives IND Approval for First-in-Class Dual-Target Molecular Glue Drug FD-001

ApicHope announced that the IND application for FD-001 capsules, the first dual-target molecular glue new drug developed using molecular glue technology by its participating company FenDiPharma, has received tacit approval from the National Medical Products Administration (NMPA). The indications include the treatment of hematological malignancies such as acute myeloid leukemia (AML), multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Currently, ApicHope holds a 25% stake in FenDiPharma through its wholly-owned subsidiary RuiAo Bio. (Securities Times)